» Articles » PMID: 8331723

Functional and Immunologic Characterization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Containing Deletions of the Major Variable Regions

Overview
Journal J Virol
Date 1993 Aug 1
PMID 8331723
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

Deletions of the major variable regions (V1/V2, V3, and V4) of the human immunodeficiency virus type 1 (HIV-1) gp120 exterior envelope glycoprotein were created to study the role of these regions in function and antigenicity. Deletion of the V4 region disrupted processing of the envelope glycoprotein precursor. In contrast, the deletion of the V1/V2 and/or V3 regions yielded processed exterior envelope glycoproteins that retained the ability to interact with the gp41 transmembrane glycoprotein and the CD4 receptor. Shedding of the gp120 exterior glycoprotein by soluble CD4 was observed for the mutant with the V3 deletion but did not occur for the V1/V2-deleted mutant. None of the deletion mutants formed syncytia or supported virus entry. Importantly, the affinity of neutralizing antibodies directed against the CD4-binding region for the multimeric envelope glycoprotein complex was increased dramatically by the removal of both the V1/V2 and V3 structures. These results indicate that, in addition to playing essential roles in the induction of membrane fusion, the major variable regions mask conserved neutralization epitopes of the HIV-1 gp120 glycoprotein from antibodies. These results explain the temporal pattern associated with generation of HIV-1-neutralizing antibodies following infection and suggest stratagems for eliciting improved immune responses to conserved gp120 epitopes.

Citing Articles

Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach.

Khatri R, Parray H, Agrahari A, Rizvi Z, Kaul R, Raj S Int J Biol Macromol. 2022; 209(Pt A):1359-1367.

PMID: 35469951 PMC: 9033297. DOI: 10.1016/j.ijbiomac.2022.04.148.


Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway.

Mielke D, Bandawe G, Pollara J, Abrahams M, Nyanhete T, Moore P Front Immunol. 2020; 10:2875.

PMID: 31921139 PMC: 6919271. DOI: 10.3389/fimmu.2019.02875.


Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope.

Weidenbacher P, Kim P Proc Natl Acad Sci U S A. 2019; 116(20):9947-9952.

PMID: 31028143 PMC: 6525525. DOI: 10.1073/pnas.1822062116.


Sequential trafficking of Env and Gag to HIV-1 T cell virological synapses revealed by live imaging.

Wang L, Izadmehr S, Kamau E, Kong X, Chen B Retrovirology. 2019; 16(1):2.

PMID: 30646921 PMC: 6334456. DOI: 10.1186/s12977-019-0464-3.


Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.

Duan H, Chen X, Boyington J, Cheng C, Zhang Y, Jafari A Immunity. 2018; 49(2):301-311.e5.

PMID: 30076101 PMC: 6896779. DOI: 10.1016/j.immuni.2018.07.005.


References
1.
Traunecker A, Luke W, Karjalainen K . Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature. 1988; 331(6151):84-6. DOI: 10.1038/331084a0. View

2.
Palker T, Clark M, Langlois A, Matthews T, Weinhold K, Randall R . Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988; 85(6):1932-6. PMC: 279895. DOI: 10.1073/pnas.85.6.1932. View

3.
BERGER E, Fuerst T, Moss B . A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. Proc Natl Acad Sci U S A. 1988; 85(7):2357-61. PMC: 279991. DOI: 10.1073/pnas.85.7.2357. View

4.
Rusche J, Javaherian K, McDanal C, Petro J, Lynn D, Grimaila R . Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A. 1988; 85(9):3198-202. PMC: 280171. DOI: 10.1073/pnas.85.9.3198. View

5.
Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H . Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol. 1988; 62(6):2107-14. PMC: 253305. DOI: 10.1128/JVI.62.6.2107-2114.1988. View